Common questions about Tavaborole (FAQ)
Q: Can Tavaborole be used on fingernails or only toenails?
Regulatory documents specify that the approved indication for this medication is to treat onychomycosis, which is a fungal infection, of the toenails. The clinical studies and established guidelines are based specifically on its use for toenail infections.
Q: Is it normal to see results quickly, or is the treatment duration long?
The prescribed treatment course for this medication is long, typically lasting for 48 weeks. Because the infected nail must fully grow out and be replaced by a new, healthy nail, observable improvement is typically gradual, consistent with the slow growth cycle of the nail.
Q: What happens if I miss a day of using Tavaborole?
If an application is missed, official regulatory guidance suggests applying it as soon as the lapse is remembered. If the next application is almost due, regulatory guidance indicates that the missed dose is typically skipped, with the individual resuming the regular once-daily schedule.
Q: What is the safety classification for Tavaborole during breastfeeding?
Official labeling for the product states that it is unknown if Tavaborole is passed into human milk (excreted). Regulatory documents define this as a cautionary use scenario, and use in lactating individuals requires careful consideration.
Q: Is Tavaborole effective against all types of fungus that affect the nail?
The medicine is specifically indicated in regulatory documents for treating fungal infections of the toenails that are caused by the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. This means its official use is limited to these specific types of fungus.
Q: Is the solution supposed to cover the whole nail and surrounding skin?
Administration instructions state that the solution should cover the entire toenail surface, including the area under the nail tip, and be spread to the surrounding skin. Regulatory guidance indicates that any excess solution on the surrounding skin is typically wiped away during application.
Q: What should I do if the Tavaborole liquid gets onto healthy skin?
Regulatory instructions specify that any excess medication that comes in contact with the skin around the treated toenail is typically wiped off. This is part of the official procedural guidance for administration.
Q: Are the results from clinical trials on Tavaborole permanent?
Clinical study evidence reviewed by regulators typically includes an intermediate-term follow-up of 52 weeks. Findings from research do not fully establish long-term effects, such as the permanence of the outcomes beyond that period.
Q: Is Tavaborole absorbed into the bloodstream?
Regulatory data confirms that Tavaborole has low systemic absorption when applied topically. The active ingredient is, however, detectable in the bloodstream following application.
Q: Are there foods or drinks I should avoid when using Tavaborole?
Official patient information indicates that no formal interactions with food or drink are documented for this medicine. Unless directed otherwise by a healthcare professional, individuals typically maintain their normal diet.
Q: How is Tavaborole related to Kerydin, if at all?
Tavaborole is the active ingredient in the medication. Kerydin is the trade (brand) name under which the topical solution was originally approved by the FDA.
Q: Does Tavaborole make the nail look better right away?
Due to the long process required for a new, healthy nail to grow, the medication is not expected to produce immediate visible cosmetic changes. Improvement is typically gradual, corresponding to the long, slow growth cycle of the nail.
Q: What if I experience irritation near the application site?
If symptoms such as irritation, blistering, redness, or itching occur at the application site and are severe or do not improve, regulatory patient information highlights the importance of consulting a healthcare professional.
Q: Why does the packaging for Tavaborole include an applicator?
The medicine is packaged with a dropper assembly (applicator) to facilitate its required application. This tool ensures the precise and consistent delivery of the liquid solution to the entire affected toenail surface, including under the tip.
Q: Is there a generic version of Tavaborole available?
Regulatory-related databases, such as the FDA Orange Book, indicate that a generic version of Tavaborole is available.
Q: Does Tavaborole treat the infection or just prevent it from spreading?
The drug's mechanism of action is described in official documents as producing a fungicidal effect. This means it works by eliminating the fungal cells by inhibiting their ability to synthesize necessary proteins, which is an action to treat the infection itself.
Q: Can people with certain allergies use Tavaborole?
The medicine is formally contraindicated (prohibited) for use by individuals with a known hypersensitivity or allergy to the active ingredient, Tavaborole, or to any of the other inactive ingredients in the solution.
Q: Do you have to file the nail down before using Tavaborole?
Official regulatory information confirms that mechanical nail debridement (filing or trimming away diseased portions of the nail) is not a required step for using this medicine.
Q: What evidence supports the use of Tavaborole for nail fungus?
The drug's efficacy and safety were determined and supported by data from two large-scale, double-blind, vehicle-controlled Randomized Controlled Trials (RCTs) reviewed by regulatory agencies.
Q: What is the risk of the fungus coming back after using Tavaborole?
The current body of research evidence is limited to an intermediate-term follow-up of 52 weeks. As a result, the risk of the infection returning (recurrence) in the long-term, beyond the studied period, is not fully characterized in the official documents.
